transplantation related autoimmune cytopenia
Conditions
Interventions
Ruxolitinib group:Weight <25kg, 2.5mg, weight = 25kg, 5mg, take orally once or twice a day
According to the condition and tolerance, the maximum dose can be increased to 10mg/time, twice a day
Prednisone group:1-2mg/kg/d to start treatment (or equivalent hormone)
Sponsors
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 70 Years
Inclusion criteria
Inclusion criteria: 1. After allogeneic transplantation, there is no limit to men and women and age; 2. Consider patients diagnosed with AIC; 3. The basic disease is stable, without progression and recurrence; 4. No active or chronic infection
Exclusion criteria
Exclusion criteria: 1.Evidence of recurrence of primary disease or recurrence after transplantation; 2.There is uncontrolled active infection;3.Severe liver and kidney dysfunction; 4.Clinically significant or uncontrolled heart disease (grade III or IV congestive heart failure); 5.Those who are allergic to lucotinib phosphate or have a more serious allergic constitution; 6.At the same time, participate in other clinical researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate after 6 months of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year overall survival;2-year disease-free survival rate;Relapse rate;Proportion of starting secondary systemic immunosuppressive therapy;Proportion of Ruxolitinib discontinued due to toxicity or intolerance;Adverse drug reactions;Lymphocyte subsets;Incidence of infection;Overall response rate after 3 months and 12 months of treatment; | — |
Countries
China
Contacts
Public ContactChen ting
Medical Center of Hematology, Xinqiao Hospital of Army Medical University
Outcome results
None listed